Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus

Human Pathology

Volumn 30, Issue 11, 1999, Pages 1309-1313

  Younes, Mamoun ^a   Schwartz, Mary R ^b   Finnie, Delia ^b   Younes, Anas ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Apoptosis; Cancer; Dysplasia; Fas; FasL; Inflammation

Indexed keywords

FAS LIGAND;

ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; INTESTINE METAPLASIA; MALIGNANT TRANSFORMATION;

EID: 0032719020     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90061-8     Document Type: Article

References (28)

1. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747-1756, 1989
2. Oehm A, Behrmann I, Falk W, et al: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J Biol Chem 267:10709-10715, 1992
3. Itohi N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991
4. Suda T, Takahashi T, Golstein P, et al: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993
5. Bamberger AM, Schulte HM, Thuneke I, et al: Expression of the apoptosis-inducing Fas ligand (Fasl) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 82:3173-3175, 1997
6. Hunt JS, Vassmer D, Ferguson TA, et al: Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 158:4122-4128, 1997
7. Runic R, Lockwood CJ, Ma Y, et al: Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival. J Clin Endocrinol Metab 81:3119-3122, 1996
8. Saas P, Walker PR, Hahne M, et al: Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain. J Clin Invest 99:1173-1178, 1997
9. Gratas C, Tohma Y, Barnas C, et al: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58:2057-2062, 1998
10. Leithauser F, Dhein J, Mechtersheimer G, et al: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429, 1993
11. Moller P, Koretz K, Leithauser F, et al: Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57:371-377, 1994
12. Vollmers HP, Dammrich J, Hensel F, et al: Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 79:433-440, 1997
13. Moller P, Walczak H, Reidl S, Strater J, Krammer PH. Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia. Am J Pathol 149:9-13, 1996
14. Niehans GA, Brunner T, Frizelle SP, et al: Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012, 1997
15. Gratas C, Tohma Y, Vanmeir EG, et al: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7:863-869, 1997
16. Shiraki K, Tsuji N, Shioda T, et al: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 94:6420-6425, 1997
17. Ungefroren H, Voss M, Jansen M, et al: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58:1741-1749, 1998
18. Mullauer L, Mosberger I, Chott A: Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 11:369-375, 1998
19. Strand S, Hofmann WJ, Hug H, et al: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: A mechanism of Immune evasion. Nat Med 2:1361-1366, 1996
20. Hughes SJ, Nambu Y, Soldes OS, et al: Fas/Apo-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57:5571-5578, 1997
21. Chouaib S, Asselinpaturel C, Mamichouaib F, et al: The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493-497, 1997
22. Green DR, Ware CF: Fas-Ligand: Privilege and peril. Proc Natl Acad Sci U S A 94:5986-5990, 1997
23. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 18:240-244, 1997
24. Nagata S: Fas ligand and immune evasion. Nat Med 2:1306-1307, 1996
25. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD951) in immune escape: The tumor cell strikes back. Commentary. J Immunol 158:4521-4524, 1997
26. Haggitt RC: Barrett's esophagus, dysplasia, and adenocarcinoma. HUM PATHOL 25:982-993, 1994
27. O'Brien MJ, Winawer SJ, Zauber AG, et al: The National Polyp Study: Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 98:371-379, 1990
28. Williams MS, Henkart PA: Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J Immunol 157:2395-2402, 1996